首页> 外文期刊>Neuro-Oncology >Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma
【24h】

Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma

机译:脑胶质瘤患者肿瘤位置的Voxel方向放射基因组学定位与关键分子改变

获取原文
获取原文并翻译 | 示例
           

摘要

This study aims to evaluate the impact of tumor location on key molecular alterations on a single voxel level in patients with newly diagnosed glioma.A consecutive series of n = 237 patients with newly diagnosed glioblastoma and n = 131 patients with lower-grade glioma was analyzed. Volumetric tumor segmentation was performed on preoperative MRI with a semi-automated approach and images were registered to the standard Montreal Neurological Institute 152 space. Using a voxel-based lesion symptom mapping (VLSM) analysis, we identified specific brain regions that were associated with tumor-specific molecular alterations. We assessed a predefined set of n = 17 molecular characteristics in the glioblastoma cohort and n = 2 molecular characteristics in the lower-grade glioma cohort. Permutation adjustment (n = 1000 iterations) was used to correct for multiple testing, and voxel t-values that were greater than the t-value in >95% of the permutations were retained in the VLSM results (α = 0.05, power > 0.8).Tumor location predilection for isocitrate dehydrogenase (IDH) mutant tumors was found in both glioblastoma and lower-grade glioma cohorts, each showing a concordant predominance in the frontal lobe adjacent to the rostral extension of the lateral ventricles (permutation-adjusted P = 0.021 for the glioblastoma and 0.013 for the lower-grade glioma cohort). Apart from that, the VLSM analysis did not reveal a significant association of the tumor location with any other key molecular alteration in both cohorts (permutation-adjusted P > 0.05 each).Our study highlights the unique properties of IDH mutations and underpins the hypothesis that the rostral extension of the lateral ventricles is a potential location for the cell of origin in IDH-mutant gliomas.
机译:本研究旨在评估新诊断的神经胶质瘤患者的肿瘤位置对单个体素水平上关键分子改变的影响。分析了连续的n = 237的新诊断的胶质母细胞瘤患者和n = 131的低度神经胶质瘤患者。使用半自动方法在术前MRI上进行体积肿瘤分割,并将图像记录到标准的蒙特利尔神经病学研究所152空间。使用基于体素的病变症状图谱(VLSM)分析,我们确定了与肿瘤特异性分子改变相关的特定脑区域。我们在胶质母细胞瘤队列中评估了一组预定义的n = 17分子特征,在低级神经胶质瘤队列中评估了n = 2分子特征。置换调整(n = 1000次迭代)用于校正多次测试,并且在VLSM结果中保留了大于95%置换中t值的体素t值(α= 0.05,功效> 0.8在胶质母细胞瘤和低级神经胶质瘤队列中均发现了异柠檬酸脱氢酶(IDH)突变肿瘤的肿瘤位置偏爱,每组均显示在额叶中与侧脑室延展相邻的一致优势(排列调整后的P = 0.021) (对于胶质母细胞瘤而言,则为0.013;对于较低等级的神经胶质瘤群组而言,则为0.013)。除此之外,VLSM分析未显示两个队列中的肿瘤位置与任何其他关键分子改变之间存在显着相关性(排列调整后的P> 0.05)。我们的研究强调了IDH突变的独特性质,并支持以下假设侧脑室的延展性是IDH突变型神经胶质瘤中起源细胞的潜在位置。

著录项

  • 来源
    《Neuro-Oncology》 |2018年第11期|1517-1524|共8页
  • 作者单位

    Department of Neuroradiology, University of Heidelberg Medical Center, Heidelberg, Germany.;

    Department of Neuroradiology, University of Heidelberg Medical Center, Heidelberg, Germany.;

    Department of Neuropathology, University of Heidelberg Medical Center, Heidelberg, Germany.;

    Department of Neuroradiology, University of Heidelberg Medical Center, Heidelberg, Germany.;

    Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;

    Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany.;

    Division of Pediatric Neurooncology, DKFZ, Heidelberg, Germany.;

    German Cancer Consortium (DKTK) Core Center Heidelberg, Heidelberg, Germany.;

    Neurology Clinic, University of Heidelberg Medical Center, Heidelberg, Germany.;

    Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany.;

    Division of Pediatric Neurooncology, DKFZ, Heidelberg, Germany.;

    German Cancer Consortium (DKTK) Core Center Heidelberg, Heidelberg, Germany.;

    Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;

    1Department of Neurosurgery, University of Heidelberg Medical Center, Heidelberg, Germany.;

    1Department of Radiation Oncology, University of Heidelberg Medical Center, Heidelberg Institute of Radiation Oncology (HIRO) and National Center for Radiation Research in Oncology (NCOR), Heidelberg, Germany.;

    1Molecular and Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital and DKFZ, Heidelberg, Germany.;

    1Department of Neuroradiology, University of Heidelberg Medical Center, Heidelberg, Germany.;

    1Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;

    1Department of Neurosurgery, University of Heidelberg Medical Center, Heidelberg, Germany.;

    1Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany.;

    1Division of Pediatric Neurooncology, DKFZ, Heidelberg, Germany.;

    1German Cancer Consortium (DKTK) Core Center Heidelberg, Heidelberg, Germany.;

    1Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany.;

    1Department of Neuropathology, University of Heidelberg Medical Center, Heidelberg, Germany.;

    1DKTK, Clinical Cooperation Unit Neuropathology, DKFZ, Heidelberg, Germany.;

    1Neurology Clinic, University of Heidelberg Medical Center, Heidelberg, Germany.;

    1Clinical Cooperation Unit Neurooncology, DKTK, DKFZ, Heidelberg, Germany.;

    1Department of Neuropathology, University of Heidelberg Medical Center, Heidelberg, Germany.;

    1Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute for Neuropathology, Berlin, Germany.;

    1DKTK, Partner Site Berlin, DKFZ, Heidelberg, Germany.;

    1Department of Neuroradiology, University of Heidelberg Medical Center, Heidelberg, Germany.;

    2Department of Neuroradiology, University of Heidelberg Medical Center, Heidelberg, Germany.;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号